Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
- 06 Dec 2016 Results (n=32) assessing safety and efficacy in patients with poor-risk cytogenetics or advanced refractory disease, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 11 Aug 2016 Status changed from recruiting to active, no longer recruiting.